POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.

被引：0
|
作者：
Lee, J. I. [1 ]
Jung, S. Y. [1 ]
Yug, J. S. [2 ]
Chung, E. K. [2 ]
Keedy, V. L. [3 ]
Bauer, T. M. [4 ,5 ]
Clarke, J. M. [6 ]
Hurwitz, H. [6 ]
Lee, H. [7 ]
Park, N. [7 ]
Lee, S. [7 ]
Kim, H. -K. [7 ]
Baek, I. [8 ]
Hwang, S. [8 ]
Nam, S. Y. [8 ]
Ha, I. [8 ]
Kim, S. -J. [8 ]
机构：
[1] Seoul Natl Univ, Seoul, South Korea
[2] Kyung Hee Univ, Seoul, South Korea
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Tennessee Oncol, Nashville, TN USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Natl Canc Ctr, Natl OncoVenture, Goyang, South Korea
[8] MedPacto Inc, Suwon, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-074
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [41] Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol (flavo) in patients with advanced solid tumors.
    Schwartz, GK
    Kaubisch, A
    Saltz, L
    Ilson, D
    O'Reilly, E
    Barazzuol, J
    Endres, S
    Stoltz, M
    Tong, W
    Kelsen, DP
    Spriggs, D
    CLINICAL CANCER RESEARCH, 1999, 5 : 3754S - 3754S
  • [42] A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
    Rudin, C. M.
    Jimeno, A.
    Miller, W. H.
    Eigl, B. J.
    Gettinger, S. N.
    Chang, A. L. S.
    Faia, K.
    Sweeney, J.
    Loewen, G.
    Ross, R. W.
    Weiss, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Sharma, Sunil
    Shih, Chengkon
    O'Neil, Bert H.
    Zhou, Qinghong
    Ding, Yuli
    Ou, Na
    Yu, Tingting
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in patients with advanced solid tumors.
    Sharma, Sunil
    Kang, Yoon-Koo
    Weis, John R.
    Gilcrease, Glynn Weldon
    Davidson, Cynthia
    Kingsford, Rachel
    Collett, Joan
    Orgain, Nicole
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Park, Sook Ryun
    Yoo, Hee-Won
    Kim, Sung-Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
    Su Young Jung
    Sunjin Hwang
    Jeffery M. Clarke
    Todd M. Bauer
    Vicki L. Keedy
    Hukeun Lee
    Neunggyu Park
    Seong-Jin Kim
    Jangik I. Lee
    Investigational New Drugs, 2020, 38 : 812 - 820
  • [46] Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
    Jung, Su Young
    Hwang, Sunjin
    Clarke, Jeffery M.
    Bauer, Todd M.
    Keedy, Vicki L.
    Lee, Hukeun
    Park, Neunggyu
    Kim, Seong-Jin
    Lee, Jangik, I
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 812 - 820
  • [47] Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors.
    Drevs, J
    Medinger, M
    Mross, K
    Zirrgiebel, U
    Strecker, R
    Unger, C
    Puchalski, TA
    Fernandes, N
    Roberston, J
    Siegert, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192S
  • [48] A phase I study of the VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in patients with advanced solid tumors: Safety, pharmacokinetics, and dceMRI.
    Herbst, R
    Rugo, H
    Liu, G
    Park, J
    Kies, M
    Pithavala, Y
    McShane, T
    Evelhoch, J
    Steinfeldt, H
    Reich, S
    Freddo, J
    Wilding, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6265S - 6265S
  • [49] Phase I study of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors.
    Cescon, David W.
    Hansen, Aaron Richard
    Razak, Albiruni Ryan Abdul
    Stayner, Lee-Anne
    Hilton, John Frederick
    Renouf, Daniel John
    Denny, Trisha
    Fletcher, Graham
    Mak, Tak W.
    Bray, Mark R.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
    Herbert I. Hurwitz
    Roger B. Cohen
    J. Patrick McGovren
    Samit Hirawat
    William P. Petros
    Yutaka Natsumeda
    Tomoko Yoshinari
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 139 - 147
12345